



WHERE MEDICAL AND RADIATION ONCOLOGY MEET: INTEGRATING STATE OF THE ART STRATEGIES

27 February - 1 March 2019
Tel Aviv, Israel

Chairs: J. Bernier, CH - F. Calvo, ES - D. Vorobiof, ZA/IL

Host Chair: A. Kuten, IL

Local Organizing and Scientific Committee:

R. Pfeffer, IL - I. Ben Aharon, IL - S. Paluch-Shimon, IL

J. Bar, IL - W. Mermershtain, IL - F. Atrash, IL

AROME Co-Organizers: J. Gligorov, FR
Y. Belkacemi, FR - M. Ozsahin, CH

Held in collaboration with



With the support of



SECOND ANNOUNCEMENT

FOREWORD

This 3-day ESO course is dedicated to the latest developments in the local and systemic personalized management of breast cancer, gastro-intestinal cancer, lung cancer and cancer of the head & neck. Lectures will be given by a faculty consisting of leading European and Israeli cancer experts who will focus on innovative treatment strategies and combination of systemic therapy and precision radiotherapy. The course is open to all cancer professionals - medical and radiation oncologists, surgical oncologists, gastroenterologists, pulmonologists and cancer biologists. Oncology nurses, RT physicists and technologists as well as medical students are welcome.

LEARNING OBJECTIVES

- Update the knowledge in the local and systemic personalized management of breast cancer, gastro-intestinal cancer, lung cancer and cancer of the head & neck
- Become aware of innovative strategies in combined modality therapy of the above malignancies
- Learn how to incorporate the innovative strategies in drug therapy and precision radiotherapy in daily practice

OFFICIAL LANGUAGE

The course will be held in English and no translation will be provided.

BADGE

The name badge is the only official evidence of registration and should be worn at all times during the course.

INSURANCE

The organisers bear no responsibility for untoward events in relation to the participation in the course. Participants are advised to take out their own personal and travel insurance.

CME ACCREDITATION

Participants will be entitled to receive a certificate of attendance at the close of the course by completing the online evaluation questionnaire.

Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA). Information on the status of the applications can be obtained from the organising secretariat.

FACULTY (as of September 2018)

F. Atrash, Augusta Victoria Hospital, Dept. of Oncology, Jerusalem, IL
J. Bar, Sheba Medical Center, Institute of Oncology, Ramat Gan, IL
E. Bar-Meir, Padeh Poria Medical Center, Plastic Surgery Dpt., Tiberias, IL
Y. Belkacemi, Hôpital Henri Mondor, Radiation Oncology and Breast Center Dpt., Creteil, FR
A. Ben Nun, Sheba Medical Center Israel, Thoracic Surgery Dpt., Ramat Gan, IL
R. Ben Yosef, Rambam Health Care Center, Radiation Oncology Dpt., Haifa, IL
I. Ben-Aharon, Davidoff Center, Rabin Medical Center, Dept. of Oncology, Petach Tikva, IL
N. Ben-Baruch, Kaplan Medical Center, Dept. Of Oncology, Rehovot, IL
D. Benchimol, University Hospital of Nice, Dept. of General Surgery and Digestive Oncology, Nice, FR
R. Berger, Sheba Medical Center, Oncology Dept., Tel Hashomer, IL
J. Bernier, Genolier Cancer Center, Dept. of Radio-Oncology, Genolier, CH
S. Billan, Rambam Health Care Campus, Oncology Dpt., Haifa, IL
B. Brenner, Institute of Oncology, Davidoff Cancer Center - Rabin Medical Center, Petach Tikva, IL
P. Calvo Manuel, Clinica Universidad de Navarra, Dept. of Radiation Oncology, Pamplona, Navarra, ES
R. Catane, Sheba Medical Centre, Dept. of Oncology, Ramat Gan, IL
R. Dziadziszko, Medical University of Gdansk, Oncology and Radiotherapy Dpt., Gdansk, PL
P. Franco, Università di Torino, Scuola di Medicina, Dept. of Oncology, Radiation Oncology, Torino, IT
O. Gentilini, St. Raffaele Hospital, Dept. of Breast Surgery, Milan, IT
R. Geva, Tel Aviv Sourasky Medical Centre, Dept. of Oncology, Tel Aviv, IL
E. Gez, Ziv Medical Center, Oncology Dept., Zefat, IL
J. Gligorov, APHP Tenon, IUC-UPMC, Sorbonne University, Dept. of Medical Oncology, Paris, FR
M. Gottfried, Meir Medical Center, Oncology Dpt., Kfar Saba, IL
K. Hausermans, Uz Leuven, Radiation Oncology Department, Leuven, BE
M. Inbar, Assuta Medical Centres, Oncology Dpt., Tel Aviv, IL
B. Kaufman, Sheba Medical Center, Dept. of Oncology, Ramat Gan, IL
D. Keizman, Meir Medical Center Genitourinary Oncology Dpt., Kfar-Saba, IL
A. Kuten, Italian Hospital of Haifa, Dept. of Oncology, Haifa, IL
P. Lara, Dr Negrin Las Palmas University Hospital, Radiation Oncology Dpt., Las Palmas, ES
Y. Lawrence, Sheba Medical Center, Radiation Dpt., Ramat Gan, IL
R. Leibowitz, Sheba Medical Center, Oncology Dpt., Tel-Hashomer, IL
E. Levy Lahad, Shaare Zedek Medical Center, Medical Genetics Institute, Jerusalem, IL
S. Man, Soroka University Medical Center, Dept. of Oncology, Beer Sheva, IL
E. M. Marom, The HaimSheba Medical Center, Tel Aviv University, Diagnostic Radiology Dpt., Ramat Gan, IL
W. Mermershtain, Beer Sheva, IL
E. Ozsahin, Centre Hospitalier Universitaire Vaudois (CHUV), Dept. of Radiation Oncology, Lausanne, CH
S. Paluch-Shimon, Shaare Zedek Medical Centre, Breast Cancer Dpt., Jerusalem, IL
F. Peccatori, European Institute of Oncology, Dept. of Fertility and Procreation in Oncology, Milano, IT
A. Peer Rambam, Medical Center Genitourinary Oncology Dpt., Haifa, IL
N. Peled, Hod Hasharon, IL
R. Pfeffer, Sheba Medical Center, Dept. Of Oncology, Tel Hashomer, IL
P. Poortmans, Curie Institute, Dept. of Radiation Oncology, Paris, FR
G. Rennert, Carmel Medical Ctr., Department of Community Medicine and Epidemiology, Haifa, IL
E. Smyth, Royal Marsden Hospital, London, UK
E. Shacham Shmueli, Sheba Medical Hospital, Oncology Dpt., Ramat Gan, IL
Y. Shiloh, Tel Aviv University, Human Molecular Genetics and Biochemistry Dpt, Tel Aviv, IL
K. Shulman, Hillel Yaffe Medical Center, Oncology Dpt., Hadera, IL
Z. Symon, Sheba Medical Center, Radiation Oncology Dpt., Ramat Gan, IL
P. Van Houtte, Institute Jules Bordet, Dept. of Radiation Oncology, Bruxelles, BE
D. Vorobiof, Sandton Oncology Centre, Oncology Dpt., Johannesburg, SA
M. Wygoda, Sharett Institute of Oncology Hadassah-Hebrew University Hospital, Radiotherapy Dpt., Jerusalem, IL
M. Wollner, Rambam Health Care Campus, Oncology Dpt., Haifa, IL
R. Yerushalmi, Rabin Medical Center, Beilinson Campus, Petach Tikva, IL
A. Zer, Rabin Medical Centre, Lung Cancer Clinic, Petach Tikva, IL
M. Ziv, Israel Cancer Association, Director Office, Givatayim, IL

Updates to the list of the faculty will be published on future announcements and at www.eso.net.

PROGRAMME (as of September 2018)

Wednesday, 27 February 2019

8:00 Welcome and opening address

A. Kuten, IL - J. Bernier, CH
F. Calvo, ES - M. Ziv, IL
M. Mermershtain, IL

BREAST CANCER: THE IMPACT OF MOLECULAR SUBTYPING ON LOCO-REGIONAL AND SYSTEMIC TREATMENT OF BREAST CANCER

Chairs: N. Ben-Baruch, IL
M. Inbar, IL

8:30 Impact on surgical management

O. Gentilini, IT

8:50 Impact on systemic therapy

J. Gligorov, FR

9:10 Impact on loco-regional therapy and radiotherapy in the setting of breast reconstruction

Y. Belkacemi, FR

9:30 Impact on multimodality care in the neo-adjuvant setting

R. Yerushalmi, IL

9:50 Regional lymph node treatment in breast cancer: when, which and how

P. Poortmans, FR

10:15 *Coffee break*

BREAST CANCER- SPECIAL POPULATIONS & UNIQUE ASPECTS OF CARE

Chairs: B. Kaufman, IL
E. Bar-Meir, IL

10:45 Genetic testing for hereditary cancer - state of the art

E. Levy-Lahad, IL

11:00 Reproductive considerations in the BRCA+ breast cancer patient

F. Peccatori, IT

11:15 Management of the BRCA+ patient with breast cancer

S. Paluch-Shimon, IL

11:30 Unique surgical considerations in young patients and BRCA+ patients

O. Gentilini, IT

11:45 *Tumour board* - case discussions

12:30 *Lunch*

LUNG CANCER - INTEGRATIVE APPROACHES

Chairs: R. Pfeffer, IL - N. Peled, IL

13:30 Interpretation pitfalls in lung cancer follow up

E.M. Marom, IL

13:50 Early stage NSCLC - SBRT vs. surgery

P. van Houtte, BE

14:10 Immunotherapy in early stage NSCLC

J. Bar, IL

14:30 *Coffee break*

LUNG CANCER - LOCALLY ADVANCED

Chairs: A. Zer, IL - M. Wollner, IL

15:00 Stage III NSCLC - radiotherapy aspects

P. van Houtte, BE

15:20 Stage III NSCLC - systemic treatments

R. Dziadziuszko, PL

15:40 Stage III NSCLC - surgical approach

A. Ben-Nun, IL

16:00 Lung cancer panel - cases

Moderator: M. Gottfried, IL +
all of the above speakers

CANCER OF THE HEAD AND NECK

Chairs: J. Bernier, CH - S. Billan, IL

8:30 Integration of RT and systemic therapy (chemo-, targeted-, immune-therapy) in cancer of the Head and Neck

M. Ozsahin, CH

GENITO-URINARY CANCER (PART I)

Chair: E. Gez, IL

9:00 Localised bladder cancer

M. Wygoda, IL

9:20 Systemic therapy of kidney and bladder cancer

D. Keizman, IL

9:40 Non-metastatic prostate cancer-selection of therapy

Z. Symon, IL

10:10 *Coffee break*

GENITO-URINARY CANCER (PART II)

Chairs: R. Berger, IL - E. Gez, IL

10:40 Metastatic Prostate cancer - systemic therapy

A. Peer, IL

11:00 Metastatic Prostate cancer - is there a role for loco-regional therapy?

R. Ben Yosef, IL

11:20 Case presentation and panel discussion

Moderator: R. Leibowitz, IL
+ all of the above speakers

12:15 *Lunch*

GASTRO INTESTINAL CANCER: LOCALLY ADVANCED DISEASE

Chairs: D. Vorobiof, ZA/IL
B. Brenner, IL

13:15 Neoadjuvant chemo-RT vs perioperative chemotherapy in GEJ cancer

E. Smyth, UK

13:45 Pancreatic Cancer: the role of loco-regional therapy

Y. Lawrence, IL

14:15 Rectal Cancer: New venues of treatment in rectal cancer. Can we reduce the need for radiotherapy or radical surgery?

K. Haustermans, BE

14:45 *Coffee break*

GASTRO INTESTINAL CANCER: METASTATIC DISEASE

Chairs: K. Shulman, IL
S. Man, IL

15:15 The role of cytoreductive surgery and HIPEC in metastatic CRC

D. Benchimol, IL

15:45 The role of metastasis targeted therapy in GI tumors

R. Geva, IL

16:15 Case presentation and panel discussion

Moderator: E. Shacham Shmueli
and all of the above speakers

Friday, 1 March 2019

**CAN WE CURE METASTATIC DISEASE? (OLIGOMETETS,
IMMUNE SYSTEM, GENOMICS & PROTEOMICS)**

Chairs: F. Atrash, IL
R. Catane, IL

- 8:30** Oligometastases - do they exist and can we change the treatment paradigm R. Pfeffer, IL
- 8:55** Radiation effects on the immune system J. Bar, IL
- 9:15** Genomic considerations in the selection of treatment G. Rennert, IL
- 9:40** The cancer genome landscape and omics - a deeper insight into cancer biology I. Ben-Aharon, IL
- 10:00** Maintenance of genome stability: at the crossroads between cancer causation - and treatment Y. Shiloh, IL
- 10:30** *Coffee break*

CANCER EDUCATION

- 11:00** European School of Oncology - opportunities for on-line cancer education P.F. Franco, IT
- 11:20** Oncology and radiotherapy training in the 21st century: where are we going P. Lara, ES
- 11:50** What is needed to improve cancer education in medical schools R. Pfeffer, IL
- 12:10** Minimal requirements for cancer care in the Mediterranean Area: AROME consensus Y. Belkacemi, CH - J. Gligorov, FR
- 12:30** *Closing ceremony* R. Pfeffer, IL
- 12:45** *Lunch*

The final programme will be published on the ESO website and on future announcements.

GENERAL INFORMATION

ORGANISING SECRETARIAT

European School of Oncology
Via Turati 29 | 20121 Milan | Italy
Francesca Marangoni
E-mail: fmarangoni@eso.net | Phone: +39 02 85464525

LOCAL ORGANISER AND REGISTRATION

I.M. Knasim Ltd

4 Ariel Sharon St., Givatayim
Ayelet Levy
knasim@imknasim.co.il
Tel: +972-3-6081520
Fax: +972-3-6081522

VENUE

Kfar Maccabiah Hotel

Perets Bernstein 7 st. P.O. Box 919
Ramat-Gan
5224771 Israel
www.kmc-hotel.co.il

HOTEL ACCOMMODATION

Accommodation at the course venue (Kfar Maccabiah Hotel) may be reserved through I.M. Knasim. For further information, please contact knasim@imknasim.co.il.

REGISTRATION

The registration fee includes participation in all sessions, coffee breaks and lunches as described in the programme and access to the event-dedicated website.

REGISTRATION FEES: (Israeli shekels)

	Pre-registration (by 17 February 2019)	On site (from 18 February 2019)
Regular fee	IS 200	IS 300
Discounted fee* (see below)	IS 120	IS 180

* Resident doctors in training, physicists, radiotherapy technologists, nurses, cancer biologists, dosimetrists

* Discounted fee for participants from lower- and upper-middle-income economies as defined by The World Bank

REGISTRATION FORM - WHERE MEDICAL AND RADIATION ONCOLOGY MEET | 27.2 - 3.3 2019 | Tel Aviv | IsraelPlease fill in this form in BLOCK CAPITALS and send by by **17 February** to:I.M. Knasim Ltd | Attn. Mrs. Ayelet Levy | 4 Ariel Sharon St., Givatayim | E mail: knasim@imknasim.co.il

Tel: +972-3-6081520 | Fax: +972-3-6081522

PARTICIPANT'S DETAILS Dr. Prof. Mrs. Mr.

Family name First name

Institute

Department

Street

Zip Code Town Country

Phone Fax Mobile

Email

Profession

Specialisation Main field

VAT number (*compulsory for self-employed persons*)Fiscal code (*Italian residents only*)**If your invoice details are different to those above, please complete the following section:**

Invoice contact person

Address

Phone email

VAT number (*compulsory for self-employed persons*)Fiscal Code (*Italian residents only*)**Pre-registration fees** (Israeli shekels) are available till **17 February**

	Pre-registration (by 17 February 2019)	On site (from 17 February 2019)
Regular fee	<input type="checkbox"/> IS 200	<input type="checkbox"/> IS 300
Discounted fee	<input type="checkbox"/> IS 120	<input type="checkbox"/> IS 180

PAYMENT DETAILS:**The registration is processed when payment accompanies the form** (*credit card details or copy of bank transfer*) Visa/Mastercard Card Number / / /
Expire date / CV2 code

Holder's name: and signature

 BANK TRANSFER with no cost to the beneficiary (please provide a copy of the bank transfer):**Bank:** UBank Ltd. | 38 Rothschild Blvd. | Tel Aviv | Bank no. 26 | Branch 287**Beneficiary:** A.M. Assemblies Ltd**Account number:** 776831**IBAN:** IL370262870000000776831 | **SWIFT CODE:** FIRBIL2**Reference:** "WHERE MEDICAL AND RADIATION ONCOLOGY MEET " + participant's nameUnless written objection is made, participants authorise ESO to use their personal data according to the regulation as specified in Article 13 DLGS 196, available at www.eso.net or on request at fax number +39 02 8546 4545.

Signature Date